Oliver John Semmes Selected Research

cyclo-VEGI

1/2018	A Lipidomics Approach to Identifying Key Lipid Species Involved in VEGF-Inhibitor Mediated Attenuation of Bleomycin-Induced Pulmonary Fibrosis.
1/2016	A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Oliver John Semmes Research Topics

Disease

4	Infections 01/2021 - 06/2012
2	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/2020 - 01/2016
2	Genomic Instability 01/2020 - 01/2016
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2018 - 01/2016
1	Prostatic Neoplasms (Prostate Cancer) 04/2024
1	Xeroderma Pigmentosum (Kaposi's Disease) 01/2021
1	Idiopathic Pulmonary Fibrosis 01/2018
1	Cytomegalovirus Infections (Inclusion Disease) 06/2012
1	Neoplasms (Cancer) 04/2006

Drug/Important Bio-Agent (IBA)

3	Proteins (Proteins, Gene)FDA Link 01/2016 - 06/2012
2	Biomarkers (Surrogate Marker)IBA 04/2024 - 04/2006
2	Oncogene Proteins (Oncogene Protein)IBA 01/2021 - 01/2020
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 01/2016
2	cyclo-VEGIIBA 01/2018 - 01/2016
2	Bleomycin (Blenoxane)FDA LinkGeneric 01/2018 - 01/2016
1	bis(p-chlorophenyl)acetic acid (DDA)IBA 04/2024
1	4- (4- dihexadecylaminostyryl)- N- methylpyridium (DiA)IBA 04/2024
1	Trans-Activators (Trans-Acting Factor)IBA 01/2021
1	Small Interfering RNA (siRNA)IBA 01/2021
1	EndonucleasesIBA 01/2021
1	ribonuclease HIIBA 01/2021
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 01/2020
1	LipidsIBA 01/2018
1	DNA (Deoxyribonucleic Acid)IBA 01/2016
1	MicroRNAs (MicroRNA)IBA 06/2012

Therapy/Procedure

2	Therapeutics 01/2018 - 01/2016